Annual report pursuant to Section 13 and 15(d)

STOCKHOLDERS' EQUITY (Tables)

v3.21.1
STOCKHOLDERS' EQUITY (Tables)
12 Months Ended
Dec. 31, 2020
Stockholders Equity Abstract  
Schedule of assumptions

 

 

Years Ended

 

 

 

December 31,

2020

 

 

December 31,

2019

 

Expected term

 

5.5-6.3 years

 

 

5.8-6.3 years

 

Volatility

 

62-70

%

 

54-63

%

Dividend yield

 

 

0.0

 

 

 

0.0

 

Risk-free interest rate

 

0.33-1.68

%

 

1.36-2.92

%

Schedule of stock option activity

 

 

Shares

 

 

Weighted Average Exercise Price

 

Options outstanding, vested and expected to vest at December 31, 2018

 

 

4,342,231

 

 

$ 5.16

 

Forfeited

 

 

(169,993 )

 

$ 3.97

 

Expired

 

 

(19,983 )

 

$ 4.60

 

Granted

 

 

1,508,000

 

 

$ 3.49

 

Exercised

 

 

(29,904 )

 

$ 2.84

 

Options outstanding, vested and expected to vest at December 31, 2019

 

 

5,630,351

 

 

$ 4.76

 

Forfeited

 

 

(141,724 )

 

$ 3.81

 

Expired

 

 

(27,482 )

 

$ 4.26

 

Granted

 

 

1,468,412

 

 

$ 2.93

 

Exercised

 

 

(6,626 )

 

$ 2.03

 

Options outstanding, vested and expected to vest at December 31, 2020

 

 

6,922,931

 

 

$ 4.40

 

 

 

 

 

 

 

 

 

 

Options exercisable

 

 

4,544,902

 

 

$ 5.01

 

Summary of outstanding and exercisable options by price range

 

 

Stock Options Outstanding

 

 

Stock Options Exercisable

 

Range of Exercise Prices

 

Options Outstanding

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

 

Options Outstanding

 

 

Weighted Average Remaining Contractual Life (Years)

 

 

Weighted Average Exercise Price

 

 

Aggregate Intrinsic Value

 

$2.04 - $3.20

 

 

1,328,220

 

 

 

9.2

 

 

$ 2.80

 

 

$ -

 

 

 

140,474

 

 

 

8.3

 

 

$ 2.95

 

 

$ -

 

$3.22 - $4.83

 

 

3,925,951

 

 

 

6.9

 

 

$ 3.62

 

 

 

-

 

 

 

2,787,632

 

 

 

6.6

 

 

$ 3.64

 

 

 

-

 

$4.84 - $7.26

 

 

520,607

 

 

 

5.5

 

 

$ 5.51

 

 

 

-

 

 

 

468,643

 

 

 

5.2

 

 

$ 5.48

 

 

 

-

 

$7.56 - $10.80

 

 

1,148,153

 

 

 

2.2

 

 

$ 8.39

 

 

 

-

 

 

 

1,148,153

 

 

 

2.2

 

 

$ 8.39

 

 

 

-

 

 

 

 

6,922,931

 

 

 

6.5

 

 

$ 4.40

 

 

$ -

 

 

 

4,544,902

 

 

 

5.4

 

 

$ 5.00

 

 

$ -

 

Schedule of granted Restricted Stock Units

 

 

Shares

 

 

Weighted

Average Grant

Date Fair Value

 

Balance at December 31, 2019

 

 

-

 

 

$ -

 

Granted

 

 

361,000

 

 

$ 2.82

 

Vested

 

 

(15,000 )

 

$ 2.92

 

Forfeited

 

 

(20,000 )

 

$ 2.83

 

Balance at December 31, 2020

 

 

326,000

 

 

$ 2.81

 

Stock-based compensation expense

 

 

2020

 

 

2019

 

Research and development

 

$ 471,146

 

 

$ 360,569

 

Plasma center operating expenses

 

 

33,464

 

 

 

51,340

 

Selling, general and administrative

 

 

2,107,577

 

 

 

2,047,025

 

Cost of product revenue

 

 

242,935

 

 

 

191,843

 

Total stock-based compensation expense

 

$ 2,855,122

 

 

$ 2,650,777